Notes to Condensed Consolidated Financial
Statements
(Unaudited)
1. Nature of Operations
Description of the Business
The Company was incorporated on March 15,
2000 in California and reincorporated as a Delaware corporation in September 2001 under the name KaloBios Pharmaceuticals, Inc.
Effective August 7, 2017, the Company changed its legal name to Humanigen, Inc. During February
2018, the Company completed the restructuring transactions announced in December 2017 and continued its transformation into a clinical-stage
biopharmaceutical company by further developing its clinical stage portfolio of immuno-oncology and immunology monoclonal
antibodies.
The Company is focusing its efforts on the
development of its lead product candidate, lenzilumab™, its
proprietary Humaneered® (“Humaneered”) anti-human granulocyte-macrophage colony-stimulating factor (“GM-CSF”)
monoclonal antibody. Lenzilumab is a monoclonal antibody that has been demonstrated in animal models to neutralize GM-CSF, a cytokine
that the Company believes is of critical importance in the hyperinflammatory cascade, sometimes referred to as cytokine release
syndrome (“CRS”) or cytokine storm, associated with COVID-19, chimeric antigen receptor T-cell (“CAR-T”)
therapy and acute Graft versus Host Disease (“GvHD”) associated with bone marrow transplants. GM-CSF neutralization
with lenzilumab has been shown to reduce downstream inflammatory cytokines, prevent CRS and reduce its associated neurologic toxicities
in-vivo in validated preclinical human xenograft models (Blood. 2019 Feb 14;133(7):697-709).
Lenzilumab is currently in a phase 3, multicenter,
double-blind, placebo-controlled registrational trial for hospitalized, hypoxic patients with COVID-19 pneumonia. Based on discussions
with the U.S. Food and Drug Administration (“FDA”), including a recent Type B meeting, the Company believes that the
phase 3 trial could lead to a potential filing of an Emergency Use Authorization (“EUA”) application if data warrant
such a filing. If the EUA were filed and granted, the Company could begin commercialization. The Company also intends to file a
Biologics License Application (“BLA”) in 2021. Based on the discussion with FDA, the Company understands that a BLA
will require the Company to generate and present more clinical data than would be required to support an EUA.
The Company recently announced that lenzilumab
will be included in the ACTIV-5 “Big Effect Trial” (ACTIV-5/BET). This study is sponsored by the National Institutes
of Health (“NIH”). ACTIV-5/BET is designed to determine whether certain approved therapies or investigational drugs
in late-stage clinical development show promise against COVID-19 and, therefore, merit advancement into larger clinical trials.
ACTIV-5/BET, which is expected to enroll at as many as 40 US sites, will evaluate lenzilumab with remdesivir, compared to placebo
and remdesivir, in hospitalized COVID-19 patients, with approximately 100 patients expected to be assigned to each study arm. The
Company is providing lenzilumab for the study, which is fully funded by NIH.
Lenzilumab is also being studied in a multicenter
phase 1b/2 potential registrational trial as a sequenced therapy with Yescarta® (axicabtagene ciloleucel) to reduce CRS and
neurotoxicity in patients with relapsed or refractory diffuse large B-cell lymphoma (“DLBCL”). This trial is being
conducted in partnership with Kite Pharmaceuticals, Inc., a Gilead company (“Kite”), which markets Yescarta. The Company
is also in the final planning stages for a Phase 2/3 trial for lenzilumab to treat patients who have undergone allogeneic hematopoietic
stem cell therapy (“HSCT”) who are at high risk for acute GvHD. The trial is expected to be conducted by the IMPACT
Partnership, a collection of 23 stem cell transplant centers located in the United Kingdom.
The Company’s proprietary, patented
Humaneered technology platform is a method for converting existing antibodies (typically murine) into engineered, high-affinity
human antibodies designed for therapeutic use, particularly with acute and chronic conditions. The Company has developed or in-licensed
targets or research antibodies, typically from academic institutions, and then applied its Humaneered technology to produce them.
Lenzilumab and the Company’s other two product candidates, ifabotuzumab and HGEN005, are Humaneered monoclonal antibodies.
The Company’s Humaneered antibodies are closer to human antibodies than chimeric or conventionally humanized antibodies and
have a high affinity for their target but low immunogenicity. The Company believes its Humaneered antibodies offer additional advantages,
such as lower likelihood to induce an inappropriate immune response or infusion related reaction, high potency, and a slow off-rate.
See Management’s Discussion and Analysis
of Financial Condition and Results of Operations in Item 2 of this Quarterly Report on Form 10-Q for additional information regarding
the business.
Liquidity and Going Concern
The Condensed Consolidated Financial Statements
for the three and nine months ended September 30, 2020 were prepared on the basis of a going concern, which contemplates that the
Company will be able to realize assets and discharge liabilities in the normal course of business. However, the Company has
incurred net losses since its inception and has negative operating cash flows. These conditions raised substantial doubt about
the Company’s ability to continue as a going concern as described in the Company’s historical Condensed Consolidated
Financial Statements included in its Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and in its Quarterly
Reports on Form 10-Q for the quarters ended March 31, 2020 and June 30, 2020.
Following completion of its underwritten
public offering in September 2020, as of September 30, 2020, the Company had cash and cash equivalents of $91.5 million (see Note
6). Accordingly, the Company re-evaluated its potential going concern disclosure requirements in accordance with ASC 205-40-50
as of September 30, 2020. Upon completion of this evaluation, the Company has concluded that its existing cash and cash equivalents
have alleviated that prior substantial doubt about the Company’s ability to continue as a going concern.
The Company believes that its cash and cash
equivalents will be sufficient to fund its planned operations and capital expenditure requirements for at least 12 months. This
evaluation is based on relevant conditions and events that are currently known or reasonably knowable. As a result, the Company
could deplete its available capital resources sooner than it currently expects, and a delay in obtaining or failure to obtain an
EUA could further constrain its cash resources. The Company has based these estimates on assumptions that may prove to be wrong,
and its operating projections, including its projected net revenue following the potential receipt of an EUA for lenzilumab in
COVID-19 patients, may change as a result of many factors currently unknown to it. If the Company is unable to raise additional
capital when needed or on acceptable terms, it would be forced to delay, reduce or eliminate its research and development programs
and commercialization efforts. Alternatively, the Company might raise funds through strategic collaborations, public or private
financings or other arrangements. Such funding, if needed, may not be available on favorable terms, or at all. The financial statements
included herein do not include any adjustments that might result from the outcome of these uncertainties.
Basis of Presentation
The accompanying interim unaudited Condensed
Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S.
GAAP”) for interim financial information and on a basis consistent with the annual consolidated financial statements and
include all adjustments necessary for the presentation of the Company’s condensed consolidated financial position, results
of operations and cash flows for the periods presented. The Condensed Consolidated Financial Statements include the accounts of
the Company and its wholly owned subsidiaries. These financial statements have been prepared on a basis that assumes that the Company
will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments
in the normal course of business. The December 31, 2019 Condensed Consolidated Balance Sheet was derived from the audited financial
statements but does not include all disclosures required by U.S. GAAP. These interim financial results are not necessarily indicative
of the results to be expected for the year ending December 31, 2020, or for any other future annual or interim period. The accompanying
unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited consolidated financial statements
and the related notes thereto included in the Company’s 2019 Form 10-K.
The preparation of financial statements
in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported
in the Condensed Consolidated Financial Statements and accompanying notes. Actual results could differ materially from those estimates.
The Company believes judgment is involved in determining the valuation of the fair value-based measurement of stock-based compensation
and warrant valuations. The Company evaluates its estimates and assumptions as facts and circumstances dictate. As future events
and their effects cannot be determined with precision, actual results could differ from these estimates and assumptions, and those
differences could be material to the Condensed Consolidated Financial Statements.
Certain prior year amounts have been reclassified
to conform to the current year presentation. Such reclassifications had no effect on prior years’ Net loss or Stockholders’
equity (deficit).
Effective 4:30 p.m. Eastern Time on September
11, 2020 (the “Effective Time”), the Company amended its charter to effect a reverse stock split at a ratio of 1-for-5
(the “Split Ratio”). No fractional shares were issued in connection with the reverse stock split. Stockholders of record
otherwise entitled to receive fractional shares of common stock received cash (without interest or deduction) in lieu of such fractional
share interests.
The reverse stock split reduced the total
number of shares of the Company’s common stock outstanding as of the Effective Time from approximately 210.9 million shares
to approximately 42.2 million shares. The par value per share and other terms of the Company’s common stock were not affected
by the reverse stock split, and the number of authorized shares of the Company’s common stock remains at 225,000,000.
The reverse stock split resulted in a proportionate
adjustment in the number of shares reserved for issuance under the Humanigen, Inc. 2020 Omnibus Incentive Compensation Plan (the
“2020 Equity Plan”), such that a total of 7,000,000 shares of the Company’s common stock were reserved for issuance
under the 2020 Equity Plan following the Effective Time. In addition, proportionate adjustments were made to the number of shares
covered by, and the exercise price applicable to, each outstanding stock option award under the Humanigen, Inc. 2012 Equity Incentive
Plan (the “2012 Equity Plan”) and outstanding warrants issued by the Company, in each case to give effect to the Split
Ratio and the reverse stock split.
The reverse stock split was accounted for
retroactively and is reflected in our common stock, stock option and warrant activity as of and during the year ended December
31, 2019 and the periods ended September 30, 2020 and 2019. Unless stated otherwise, all share data in this Quarterly Report on
Form 10-Q have been adjusted, as appropriate, to reflect the reverse stock split.
2. Summary of Significant Accounting Policies
There have been no material changes in the
Company’s significant accounting policies since those previously disclosed in the 2019 Form 10-K.
3. Potentially Dilutive Securities
The Company’s potentially dilutive
securities, which include stock options and warrants, have been excluded from the computation of diluted net loss per common share
as the effect of including those securities would be to reduce the net loss per common share and be antidilutive. Therefore, the
denominator used to calculate both basic and diluted net loss per common share is the same in each period presented.
The following outstanding potentially dilutive
securities have been excluded from the computations of diluted net loss per common share:
|
|
As of September 30,
|
|
|
|
2020
|
|
|
2019
|
|
Options to purchase common stock
|
|
|
3,528,642
|
|
|
|
3,027,875
|
|
Warrants to purchase common stock
|
|
|
76,238
|
|
|
|
66,239
|
|
|
|
|
3,604,880
|
|
|
|
3,094,114
|
|
4. Debt
Notes Payable to Vendors
On June 30, 2016, the Company issued promissory
notes in an aggregate principal amount of approximately $1.2 million to certain claimants in accordance with the Company’s
Plan of Reorganization (the “Plan”) filed with the United States Bankruptcy Court for the District of Delaware (the
“Bankruptcy Court”) (Case No. 15-12628 (LSS) (the “Bankruptcy Case”) which became effective June 30, 2016,
at which time the Company emerged from its Chapter 11 bankruptcy proceedings. The notes were unsecured, accrued interest at 10%
per annum and became due and payable in full, including principal and accrued interest on June 30, 2019. In July and August, 2019,
following the receipt of proceeds from the 2019 Bridge Notes, the Company used approximately $0.5 million of the proceeds to retire
a portion of these notes, including accrued interest. After giving effect to these payments, the aggregate principal amount and
accrued but unpaid interest on these notes approximated $1.1 million as of December 31, 2019 and the Company had accrued $0.3 million
in interest expense. In June and July 2020, the Company used the proceeds from the Private Placement (as defined below) to repay
the remaining outstanding principal including accrued and unpaid interest on these notes and the notes were extinguished. As of
September 30, 2020, all the notes have been repaid.
Advance Notes
In June, July and August, 2018 the Company
received an aggregate of $0.9 million of proceeds from advances made to the Company (the “Advance Notes”) by four different
lenders including Dr. Cameron Durrant, the Company’s Chairman and Chief Executive Officer; Cheval Holdings, Ltd. (“Cheval”),
an affiliate of Black Horse Capital, L.P. (“BHC”), the Company’s controlling stockholder at the time; and Ronald
Barliant, a director of the Company. The Advance Notes accrued interest at a rate of 7% per year, compounded annually.
In accordance with their terms, on May 30,
2019, in connection with the Company’s announcement of the Collaboration Agreement with Kite, the lenders converted the amounts
due under the Advance Notes into the Company’s common stock at the conversion price of $2.25 per share. The Company issued
a total of 435,924 shares of common stock in connection with the conversion.
2018 Convertible Notes
Commencing September 19, 2018, the Company
delivered a series of convertible promissory notes (the “2018 Notes”) evidencing an aggregate of $2.5 million of loans
made to the Company by six different lenders, including an affiliate of BHC, the Company’s controlling stockholder at the
time. The 2018 Notes accrued interest at a rate of 7% per annum and, in general, were set to mature twenty-four months from the
date the 2018 Notes were signed. The Company used the proceeds from the 2018 Notes for working capital.
The 2018 Notes were convertible into equity
securities of the Company in three different scenarios, including if the Company sold its equity securities on or before the date
of repayment of the 2018 Notes in any financing transaction that resulted in gross proceeds to the Company of less than $10 million
(a “Non-Qualified Financing”). In connection with a Non-Qualified Financing, the noteholders were able to convert their
remaining 2018 Notes into either (i) such equity securities as the noteholder would acquire if the principal and accrued but unpaid
interest thereon (the “Conversion Amount”) were invested directly in the financing on the same terms and conditions
as given to the financing investors in the Non-Qualified Financing, or (ii) common stock at a conversion price equal to $2.25 per
share (subject to ratable adjustment for any stock split, stock dividend, stock combination or other recapitalization occurring
subsequent to the date of the Notes).
The Company’s sales of shares pursuant
to the ELOC Purchase Agreement with Lincoln Park Capital Fund, LLC (“LPC”) constituted a Non-Qualified Financing. Commencing
on April 2, 2020, the holders of the 2018 Notes notified the Company of their exercise of their conversion rights under the 2018
Notes. See “2019 Convertible Notes” for additional information regarding the conversion of 2018 Notes by the holders.
As of December 31, 2019, the Company had
accrued $0.2 million in interest related to these promissory notes. Interest expense recorded during the three and nine months
ended September 30, 2020 was approximately $0 and $817 thousand, respectively.
2019 Convertible Notes
Commencing on April
23, 2019, the Company delivered a series of convertible promissory notes (the “2019 Notes” and together with the 2018
Notes, the “Convertible Notes”) evidencing an aggregate of $1.3 million of loans made to the Company. The 2019 Notes
accrued interest at a rate of 7.5% per annum and, in general, were set to mature twenty-four months from the date the 2019 Notes
were signed. The Company used the proceeds from the 2019 Notes for working capital.
The 2019 Notes were convertible into equity
securities of the Company in four different scenarios, including if the Company sold its equity securities on or before the date
of repayment of the 2019 Notes in any financing transaction that resulted in gross proceeds to the Company of less than $10 million
(a “Non-Qualified Financing”). In connection with a Non-Qualified Financing, the noteholders were able to convert their
remaining 2019 Notes into either (i) such equity securities as the noteholder would acquire if the Conversion Amount were invested
directly in the financing on the same terms and conditions as given to the financing investors in the Non-Qualified Financing,
or (ii) common stock at a conversion price equal to $6.25 per share (subject to ratable adjustment for any stock split, stock dividend,
stock combination or other recapitalization occurring subsequent to the date of the 2019 Notes).
The Company’s
sales of shares pursuant to the ELOC Purchase Agreement with LPC constituted a Non-Qualified Financing. Commencing on April 2,
2020, holders of the Convertible Notes, including Cheval, an affiliate of BHC, the Company’s controlling stockholder at the
time, notified the Company of their exercise of their conversion rights under the Convertible Notes. Pursuant to the exemption
from registration afforded by Section 3(a)(9) under the Securities Act, the Company issued an aggregate of 2,397,915 shares of
its common stock upon the conversion of $4.3 million in aggregate principal and interest on the Convertible Notes that were converted,
which obligations were retired. Of these, the Company issued 316,666 shares to Cheval. Dr. Dale Chappell, who was serving as the
Company’s ex-officio chief scientific officer at the time and currently serves as its Chief Scientific Officer, controls
BHC and reports beneficial ownership of all shares held by it and its affiliates, including Cheval. After giving effect to the
shares issued upon such conversions, no convertible notes issued in 2018 or 2019 were outstanding as of September 30, 2020.
As of December 31, 2019, the Company had
accrued $0.1 million in interest related to the 2019 Notes. Interest expense related to the 2019 Notes, recorded during the three
and nine months ended September 30, 2020, was approximately $0 and $219 thousand, respectively.
The Advance Notes, the 2018 Notes and the
2019 Notes had an optional voluntary conversion feature in which the holder could convert the notes in the Company’s common
stock at maturity at a conversion rate of $2.25 per share for the Advance Notes and the 2018 Notes and at a conversion rate of
$6.25 for the 2019 Notes. The intrinsic value of this beneficial conversion feature was $1.8 million upon the issuance of the Advance
Notes, the 2018 Notes and the 2019 Notes and was recorded as additional paid-in capital and as a debt discount which is accreted
to interest expense over the term of the Advance Notes and Notes. Interest expense includes debt discount amortization of $0 and
$785 thousand for the three and nine months ended September 30, 2020, respectively.
The Company evaluated the embedded features
within the Advance Notes, the 2018 Notes and the 2019 Notes to determine if the embedded features are required to be bifurcated
and recognized as derivative instruments. The Company determined that the Advance Notes, the 2018 Notes and the 2019 Notes contain
contingent beneficial conversion features (“CBCF”) that allow or require the holder to convert the Advance Notes, the
2018 Notes and the 2019 Notes, as applicable, to Company common stock at a conversion rate of $2.25 per share for the Advance Notes
and the 2018 Notes and $6.25 for the 2019 Notes, but did not contain embedded features requiring bifurcation and recognition as
derivative instruments. Upon the occurrence of a CBCF that results in conversion of the Advance Notes, the 2018 Notes or the 2019
Notes to Company common stock, the remaining unamortized discount will be charged to interest expense. Upon conversion of the Advance
Notes on May 30, 2019, the remaining unamortized discount was charged to interest expense. Upon the conversion of the Convertible
Notes in April 2020, the remaining related unamortized discount was charged to interest expense.
2020 Convertible Redeemable Notes
On
March 13, 2020 and March 19, 2020 (the “Issuance Dates”), the Company delivered two convertible redeemable promissory
notes (the “2020 Notes”) evidencing loans with an aggregate principal amount of $518,333 made to the Company.
The
2020 Notes accrued interest at a rate of 7.0% per annum and were set to mature on March 13, 2021 and March 19, 2021, respectively.
The 2020 Notes contained an original issue discount of $33,000 and $18,833, respectively. The Company used the proceeds from the
2020 Notes for working capital.
The
notes could be redeemed by the Company at any time before the 270th day following issuance, at a redemption price equal
to the principal and accrued but unpaid interest on the notes to the date of redemption, plus a premium that increases on day 61
and day 121 from the issuance date. Accordingly, the notes were repaid in June 2020 with proceeds from the Private Placement, and
the notes were extinguished.
The Company evaluated the embedded features
within the 2020 Notes and determined that the embedded features are required to be bifurcated and recognized as stand-alone derivative
instruments. The variable-share settlement features within the 2020 Notes qualify as redemption features and meet the net settlement
criterion for qualification as a stand-alone derivative. In determining the fair value of the bifurcated derivative, the Company
evaluated the likelihood of conversion of the 2020 Notes to Company stock. As the Company believed it would have adequate
funding prior to the six month anniversary of the 2020 Notes, the first conversion option for the holders of the 2020 Notes, and
it had the intent to either begin making amortizing payments or to pay off the 2020 Notes in their entirety prior to that date,
the fair value was determined to be $0. The original issue discount was accreted to Interest
expense and the remaining balance was charged to Interest expense upon payoff.
Interest expense related to the 2020 Notes,
recorded during the three and nine months ended September 30, 2020, was approximately $0 and $165 thousand, respectively.
Interest
expense includes the original issue discount amortization of approximately $0 and $52 thousand for the three and nine months ended
September 30, 2020, respectively.
Bridge Notes
On June 28, 2019, the Company issued three
short-term, secured bridge notes (the “June Bridge Notes”) evidencing an aggregate of $1.7 million of loans made to
the Company by three parties: Cheval , an affiliate of BHC, the Company’s controlling stockholder at the time, lent
$750,000; Nomis Bay LTD, the Company’s second largest stockholder, lent $750,000; and Dr. Cameron Durrant, the Company’s
Chief Executive Officer and Chairman of the Board of Directors (the “Board”), lent $200,000. The proceeds from the
June Bridge Notes were used to satisfy a portion of the unsecured obligations incurred in connection with the Company’s emergence
from bankruptcy in 2016 and for working capital and general corporate purposes. Of the $1.7 million in proceeds received, $950,000
was received on June 28, 2019 and was recorded as Advance notes in the Condensed Consolidated Balance Sheet as of June 30, 2019.
The remaining proceeds of $750,000 were received July 1, 2019 and recorded accordingly.
The June Bridge Notes accrued interest at
a rate of 7.0% per annum and after giving effect to multiple extensions, were set to mature on December 31, 2020. The June Bridge
Notes could become due and payable at such earlier time as the Company raised more than $3,000,000 in a bona fide financing transaction
or upon a change in control. Accordingly, the June Bridge Notes were repaid in June 2020 with proceeds from the Private Placement,
and the June Bridge Notes were extinguished.
On November 12, 2019, the Company issued
two short-term, secured bridge notes (the “November Bridge Notes” and together with the June Bridge Notes, the “2019
Bridge Notes”) evidencing an aggregate of $350,000 of loans made to the Company by two parties: Cheval, an affiliate of BHC,
our controlling stockholder at the time, lent $250,000; and Dr. Cameron Durrant, our
Chief Executive Officer and Chairman of our Board, lent $100,000. The proceeds from the November Bridge Notes were used
for working capital and general corporate purposes.
The November Bridge Notes ranked on par
with the June Bridge Notes and possessed other terms and conditions substantially consistent with those notes. The November Bridge
Notes accrued interest at a rate of 7.0% per annum and after giving effect to multiple extensions, were set to mature on December
31, 2020. The November Bridge Notes could become due and payable at such earlier time as the Company raised more than $3,000,000
in a bona fide financing transaction or upon a change in control. Accordingly, the November Bridge Notes were repaid in June 2020
with proceeds from the Private Placement.
In April 2020, the Company issued two short-term,
secured bridge notes (the “April Bridge Notes” and together with the June Bridge Notes and the November Bridge Notes,
the “Bridge Notes”) evidencing an aggregate of $350,000 of loans made to the Company: Cheval, an affiliate of BHC,
the Company’s controlling stockholder at the time, loaned $100,000, and Nomis Bay, the Company’s second largest stockholder,
loaned $250,000. The proceeds from the April Bridge Notes were used for working capital and general corporate purposes.
The April Bridge Notes ranked on par with
the June Bridge Notes and the November Bridge Notes and possessed other terms and conditions substantially consistent with them.
The notes accrued interest at a rate of 7.0% per annum and were set to mature on December 31, 2020. The April Bridge Notes could
become due and payable at such earlier time as the Company raised more than $10,000,000 in a bona fide financing transaction or
upon a change in control. Accordingly, these April Bridge Notes were repaid in June 2020 with proceeds from the Private Placement,
and these bridge notes were extinguished.
The Bridge Notes were secured by a lien
on substantially all the Company’s assets, which liens have been released.
Interest expense related to the Bridge Notes,
recorded during the three and nine months ended September 30, 2020, was approximately $0 and $66 thousand, respectively.
5. Commitments and Contingencies
Contractual Obligations and Commitments
As of September 30, 2020, other than the
retirement and conversion of certain debt described in Note 4 and the license agreements described in Note 7, there were no material
changes to the Company’s contractual obligations from those set forth in the 2019 Form 10-K.
Guarantees and Indemnifications
The Company has certain agreements with
service providers with which it does business that contain indemnification provisions pursuant to which the Company typically agrees
to indemnify the party against certain types of third-party claims. The Company accrues for known indemnification issues when a
loss is probable and can be reasonably estimated. The Company would also accrue for estimated incurred but unidentified indemnification
issues based on historical activity. As the Company has not incurred any indemnification losses to date, there were no accruals
for, or expenses related to, indemnification issues for any period presented.
6. Stockholders’ Equity
Reverse Stock Split
Effective as of 4:30 p.m. Eastern Time on
September 11, 2020 (the “Effective Time”), the Company amended its charter to effect a reverse stock split at a ratio
of 1-for-5 (the “Split Ratio”). No fractional shares were issued in connection with the reverse stock split. Stockholders
of record otherwise entitled to receive fractional shares of common stock received cash (without interest or deduction) in lieu
of such fractional share interests.
The reverse stock split reduced the total
number of shares of the Company’s common stock outstanding as of the Effective Time from approximately 210.9 million shares
to approximately 42.2 million shares. The par value per share and other terms of the Company’s common stock were not affected
by the reverse stock split, and the number of authorized shares of the Company’s common stock remains at 225,000,000.
The reverse stock split resulted in a proportionate
adjustment in the number of shares reserved for issuance under the 2020 Equity Plan, such that a total of 7,000,000 shares of the
Company’s common stock were reserved for issuance under the 2020 Equity Plan following the Effective Time. In addition, proportionate
adjustments were made to the number of shares covered by, and the exercise price applicable to, each outstanding stock option award
under the 2012 Equity Plan and outstanding warrants issued by the Company, in each case to give effect to the Split Ratio and the
reverse stock split.
The reverse stock split was accounted for
retroactively and is reflected in our common stock, stock option and warrant activity as of and during the period ended December
31, 2019 and the periods ended September 30, 2020 and 2019. Unless stated otherwise, all share data in this Quarterly Report on
Form 10-Q have been adjusted, as appropriate, to reflect the reverse stock split.
Lincoln Park Capital Purchase Agreement
On November 8, 2019, the Company entered
into a purchase agreement (the “ELOC Purchase Agreement”) and a registration rights agreement with LPC, pursuant to
which the Company had the right to sell to LPC up to $20,000,000 in shares of the Company’s common stock, $0.001 par value
per share (the “Common Stock”), subject to certain limitations and conditions set forth in the ELOC Purchase Agreement.
In connection with the signing of the ELOC
Purchase Agreement on November 8, 2019, the Company issued 141,318 shares of its common stock to LPC. The issuance of the shares
was recorded as debt issuance costs in Common stock and Additional paid-in capital with no net effect on Stockholders’ equity
(deficit).
During the months of December 2019 and January
2020, the Company issued a total of 140,000 shares for aggregate proceeds of $0.3 million under the ELOC Purchase Agreement.
On June 2, 2020, following completion of
the Private Placement described below, the Company notified LPC of its decision to terminate the ELOC Purchase Agreement. The termination
of the ELOC Purchase Agreement became effective on June 3, 2020.
2020 Private Placement
On June 1, 2020, the Company entered into
a securities purchase agreement (the “Purchase Agreement”) with certain accredited investors (the “Investors”)
to complete a private placement of our common stock (the “Private Placement”). The closing of the Private Placement
occurred on June 2, 2020 (the “Closing Date”). At the closing, the Company issued and sold 16,505,743 shares of its
common stock (the “Shares”) at a purchase price of $4.35 per share, for aggregate gross proceeds of approximately $71.8
million. The Company used a portion of the proceeds to retire certain indebtedness, as further described in Note 4 - Debt. See
Note 9 for information regarding two complaints filed against us in connection with the Private Placement.
On the Closing Date, the Company and the
Investors also entered into a registration rights agreement (the “Registration Rights Agreement”) pursuant to which
the Company agreed to prepare and file a registration statement (the “Resale Registration Statement”) for the resale
of the Shares with the Securities and Exchange Commission (the “SEC”).
Subject to certain limitations and an overall
cap, the Company may be required to pay liquidated damages to the investors at a rate of 2% of the invested capital for each occurrence
(and continuation for 30 consecutive days thereafter) of a breach by the Company of certain of its obligations under the Registration
Rights Agreement.
The Purchase Agreement also required that
the Company use its commercially reasonable efforts to achieve a listing of the Common Stock on a national securities exchange,
subject to certain limitations set forth in the Purchase Agreement. On July 6, 2020, the Company applied to have its common stock
approved for listing on the Nasdaq Capital Market. On September 18, 2020, the Company’s common stock commenced trading on
the Nasdaq Capital Market under the symbol “HGEN.”
2020 Underwritten Public Offering
On September 17,
2020, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities
LLC and Jefferies LLC, as representatives of the several underwriters, in connection with the public offering of 8,000,000 of the
Company’s shares of common stock. Pursuant to the Underwriting Agreement, the Company granted the underwriters a 30-day option
to purchase an additional 1,200,000 shares of common stock, which option was exercised
in full by the underwriters on September 18, 2020.
As a result of
the pricing of the public offering, the Company’s common stock commenced trading on the Nasdaq Capital Market under the symbol
“HGEN.”
The aggregate
gross proceeds from the sale of the full 9,200,000 shares in the offering were approximately $78.2 million. The Company expects
to use the proceeds from the offering to support its manufacturing, production and commercial preparation activities relating to
lenzilumab as a potential therapy for COVID-19 patients and for working capital and other general corporate purposes.
2020 Equity Plan
On July 27, 2020, the Board unanimously
approved, and recommended that the Company’s stockholders approve, the 2020 Equity Plan, to ensure that the Board and its
compensation committee (the “Compensation Committee”) will be able to make the types of awards, and covering the number
of shares, as necessary to meet the Company’s compensatory needs. On July 29, 2020, the 2020 Equity Plan was approved by
the holders of approximately 63% of the Company’s outstanding shares of common stock on that date. The 2020 Equity Plan became
effective on September 11, 2020 following the Effective Time of the reverse stock split.
Immediately following the Effective Time,
a total of 7,000,000 shares of the Company’s common stock were reserved for issuance under the 2020 Equity Plan. The Board
or Compensation Committee may grant the following types of awards under the 2020 Equity Plan: stock options, stock appreciation
rights, restricted stock, stock awards, restricted stock units, performance shares, performance units, cash-based awards and substitute
awards. The 2020 Equity Plan will remain in effect until the tenth anniversary of its effective date, unless terminated earlier
by the Board.
2012 Equity Plan
The 2020 Equity Plan replaced the 2012 Equity
Plan, under which no further grants will be made. However, any outstanding awards under the 2012 Equity Plan will continue in accordance
with the terms of the 2012 Equity Plan and any award agreement executed in connection with such outstanding awards. At the Effective
Time of the reverse stock split, proportionate adjustments were made to the number of shares covered by, and the exercise price
applicable to, each outstanding stock option award under the 2012 Equity Plan to give effect to the Split Ratio and the reverse
stock split.
Under the 2012 Equity Plan, the Company
could grant shares, stock units, stock appreciation rights, performance cash awards and/or options to employees, directors, consultants,
and other service providers. For options, the per share exercise price could not be less than the fair market value of a Company
common share on the date of grant. Awards generally vest and become exercisable over three to four years and expire 10 years from
the date of grant. Options generally become exercisable as they vest following the date of grant.
A summary of stock option activity for the
nine months ended September 30, 2020 under all the Company’s options plans is as follows:
|
|
Options
|
|
|
Weighted Average
Exercise Price
|
|
Outstanding at January 1, 2020
|
|
|
3,176,336
|
|
|
$
|
4.73
|
|
Granted
|
|
|
781,657
|
|
|
|
6.59
|
|
Exercised
|
|
|
(429,330
|
)
|
|
|
(3.55
|
)
|
Cancelled (expired)
|
|
|
(21
|
)
|
|
|
(58.40
|
)
|
Outstanding at September 30, 2020
|
|
|
3,528,642
|
|
|
$
|
5.30
|
|
The weighted average fair value of options
granted during the nine months ended September 30, 2020 was $5.13 per share.
The
Company valued the options granted using the Black-Scholes options pricing model and the following weighted-average assumption
terms for the nine months ended September 30, 2020:
|
Nine Months Ended
|
|
September 30, 2020
|
Exercise price
|
$1.90 - $10.64
|
Market value
|
$1.90 - $10.64
|
Expected term
|
5 - 6 years
|
Expected volatility
|
94.6% - 103.7%
|
Risk-free interest rate
|
0.28% - 1.57%
|
Expected dividend yield
|
- %
|
Stock-Based Compensation
The Company recorded stock-based compensation expense in the
Condensed Consolidated Statements of Operations as follows:
|
|
Three Months Ended September 30,
|
|
|
Nine Months Ended September 30,
|
|
|
|
2020
|
|
|
2019
|
|
|
2020
|
|
|
2019
|
|
General and administrative
|
|
$
|
909
|
|
|
$
|
419
|
|
|
$
|
1,415
|
|
|
$
|
1,813
|
|
Research and development
|
|
|
103
|
|
|
$
|
32
|
|
|
|
219
|
|
|
|
64
|
|
Total stock-based compensation
|
|
$
|
1,012
|
|
|
$
|
451
|
|
|
$
|
1,634
|
|
|
$
|
1,877
|
|
At September 30, 2020, the Company had $3.8
million of total unrecognized stock-based compensation expense, net of estimated forfeitures, related to outstanding stock options
that will be recognized over a weighted-average period of 2.4 years.
7. License and Collaboration Agreements
Kite Agreement
On May 30, 2019, the Company entered into
a collaboration agreement (the “Kite Agreement”) with Kite Pharmaceuticals, Inc., pursuant to which the Company and
Kite are conducting a multi-center Phase 1b/2 study of lenzilumab with Kite’s Yescarta in patients with relapsed or refractory
B-cell lymphoma, including diffuse large B-cell lymphoma (“DLBCL”). The primary objective of the study is to determine
the effect of lenzilumab on the safety of Yescarta.
Pursuant to the Kite Agreement, the Company
shall supply lenzilumab to the collaboration for use in the study and will contribute up to approximately $8.0 million towards
the out-of-pocket costs of the study, depending on the number of patients enrolled into the study. During the month of September
2020, the Company paid $2.0 million to Kite towards its contribution for the study, which payment was recorded as Research and
development expense in the three months ended September 30, 2020.
Mayo Agreement
On June 19, 2019 the
Company entered into an exclusive worldwide license agreement (the “Mayo Agreement”) with the Mayo Foundation for Medical
Education and Research (“Mayo”) for certain technologies used to create CAR-T cells lacking GM-CSF expression through
various gene-editing tools including CRISPR-Cas9 (GM-CSF knock-out). The license covers various patent applications and know-how
developed by Mayo in collaboration with the Company. These licensed technologies complement and broaden the Company’s position
in the GM-CSF neutralization space and expand the Company’s discovery platform aimed at improving CAR-T to include gene-edited
CAR-T cells.
Pursuant to the Mayo
Agreement, the Company agreed to pay $200,000 to Mayo within six months of the effective date, or upon completion of a qualified
financing, whichever is earlier. The Mayo Agreement also requires the payment of milestones and royalties upon the achievement
of certain regulatory and commercialization milestones. The initial payment was recorded as Research and development expense in
June 2019. The Company paid the initial payment in June 2020 subsequent to the closing of the Private Placement.
Zurich Agreement
On July 19, 2019 the
Company entered into an exclusive worldwide license agreement (the “Zurich Agreement”) with the University of Zurich
(“UZH”) for technology used to prevent or treat Graft versus Host Disease (“GvHD”) through GM-CSF neutralization.
The Zurich Agreement covers various patent applications filed by UZH which complement and broaden the Company’s position
in the application of GM-CSF and expands the Company’s development platform to include improving allogeneic Hematopoietic
Stem Cell Transplantation (“HSCT”).
Pursuant to the Zurich
Agreement, the Company paid $100,000 to UZH in July 2019. The Zurich Agreement also requires the payment of annual maintenance
fees and milestones and royalties upon the achievement of certain regulatory and commercialization milestones. The license payment
of $100,000 was recorded as Research and development expense in July 2019.
Clinical Trial Agreement with the National Institute of Allergy
and Infectious Diseases
On July 24, 2020,
the Company entered into a clinical trial agreement (the “Clinical Trial Agreement”) with the National Institute of
Allergy and Infectious Diseases (“NIAID”), part of NIH, which is part of the United States Government Department of
Health and Human Services, as represented by the Division of Microbiology and Infectious Diseases. Pursuant to the Clinical Trial
Agreement, lenzilumab will be an agent to be evaluated in NIAID-sponsored Accelerating COVID-19 Therapeutic Interventions and Vaccines
(ACTIV)-5 and Big Effect Trial (“BET”), referred to as ACTIV-5/BET, in hospitalized patients with COVID-19.
The NIH created
the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership and selected lenzilumab to
be evaluated in its ACTIV-5/BET, which will compare lenzilumab with Gilead’s investigational antiviral, remdesivir, versus
placebo plus remdesivir in hospitalized COVID-19 patients. The trial is expected to enroll 100 patients in each arm of the study
with an interim analysis for efficacy after 50 patients have been enrolled in each arm.
Pursuant to the Clinical Trial Agreement,
NIAID will serve as sponsor and will be responsible for funding, supervising and overseeing ACTIV-5/BET. The Company will be responsible
for providing lenzilumab to NIAID without charge and in quantities to ensure a sufficient supply of lenzilumab. The Clinical Trial
Agreement imposes additional obligations on the Company that are reasonable and customary for clinical trial agreements of this
nature, including in respect of compliance with data privacy laws and potential indemnification obligations.
8. Savant Arrangements
On June 30, 2016 the Company and Savant
Neglected Diseases, LLC (“Savant”) entered into an Agreement for the Manufacture, Development and Commercialization
of Benznidazole for Human Use (the “MDC Agreement”), pursuant to which the Company acquired certain worldwide rights
relating to benznidazole (the “Compound”).
In addition, on the Effective Date the Company
and Savant also entered into a Security Agreement (the “Security Agreement”), pursuant to which the Company granted
Savant a continuing senior security interest in the assets and rights acquired by the Company pursuant to the MDC Agreement and
certain future assets developed from those acquired assets.
On the effective date, the Company issued
to Savant a five-year warrant (the “Warrant”) to purchase 40,000 shares of the Company’s Common Stock, at an
exercise price of $11.25 per share, subject to adjustment. As of June 30, 2020, the Warrant was exercisable for 20,000 shares at
an exercise price of $11.25 per share. On July 20, 2020, the Company issued to Savant a total of 10,909 shares of its common stock
pursuant to a “net exercise” of the Warrant by Savant. The Warrant is not expected to vest or become exercisable for
any additional shares of the Company’s common stock.
As a result of the FDA granting accelerated
and conditional approval of a benznidazole therapy manufactured by a competitor for the treatment of Chagas disease and awarding
such competitor a neglected tropical disease PRV in August 2017, the Company ceased development of benznidazole and re-evaluated
the final two vesting milestones and concluded that the probability of achievement of these milestones had decreased to 0%.
In July 2017, the Company commenced litigation
against Savant alleging that Savant breached the MDC Agreement and seeking a declaratory judgement. Savant has asserted counterclaims
for breaches of contract under the MDC Agreement and the Security Agreement. The dispute primarily concerns the Company’s
right under the MDC Agreement to offset certain costs incurred by the Company in excess of the agreed upon budget against payments
due Savant. See Note 9, below, for more information regarding the Savant litigation. The aggregate cost overages as of June 30,
2017 that the Company asserts are Savant’s responsibility total approximately $3.4 million, net of a $0.5 million deductible.
The Company asserts that it is entitled to offset $2.0 million in milestone payments due Savant against the cost overages, such
that as of June 30, 2017, Savant owed the Company approximately $1.4 million. As of June 30, 2019, the cost overages totaled $4.1
million such that Savant owed the Company approximately $2.1 million in cost overages. Such cost overages have been charged to
Research and development expense as incurred. Recovery of such cost overages, if any, will be recorded as a reduction of Research
and development expense in the period received.
The $2.0 million in milestone payments due
Savant are included in Accrued expenses in the accompanying Condensed Consolidated Balance Sheets as of September 30, 2020 and
December 31, 2019.
9. Litigation
Savant Litigation
On July 10, 2017, the Company filed a complaint
against Savant in the Superior Court for the State of Delaware, New Castle County (the “Delaware Court”). KaloBios
Pharmaceuticals, Inc. v. Savant Neglected Diseases, LLC, No. N17C-07-068 PRW-CCLD. The Company asserted breach of contract
and declaratory judgment claims against Savant arising under the MDC Agreement. See Note 8 - “Savant Arrangements”
for more information about the MDC Agreement. The Company alleges that Savant has breached its MDC Agreement obligations to pay
cost overages that exceed a budgetary threshold as well as other related MDC Agreement representations and obligations. In the
litigation, the Company has alleged that as of June 30, 2017, Savant was responsible for aggregate cost overages of approximately
$3.4 million, net of a $0.5 million deductible under the MDC. The Company asserts that it is entitled to offset $2.0 million in
milestone payments due Savant against the cost overages, such that as of June 30, 2017 Savant owed the Company approximately $1.4
million.
On July 12, 2017, Savant removed the case
to the Bankruptcy Court, claiming that the action is related to or arises under the Bankruptcy Case from which we emerged in July
2016. In re KaloBios Pharmaceuticals, Inc., No. 15-12628 (LSS) (Bankr. D. Del.). On July 27, 2017, Savant filed an Answer
and Counterclaims. Savant’s filing alleges breaches of contracts under the MDC Agreement and the Security Agreement, claiming
that the Company breached its obligations to pay the milestone payments and other related representations and obligations. On August
1, 2017, the Company moved to remand the case back to the Delaware Court (the “Motion to Remand”).
On August 2, 2017, Savant sent a foreclosure
notice to the Company, demanding that it provide the Collateral as defined in the Security Agreement for inspection and possession
on August 9, 2017, with a public sale to be held on September 1, 2017. The Company moved for a Temporary Restraining Order (the
“TRO”) and Preliminary Injunction in the Bankruptcy Court on August 4, 2017. Savant responded on August 7, 2017. On
August 7, 2017, the Bankruptcy Court granted the Company’s motion for a TRO, entering an order prohibiting Savant from collecting
on or selling the Collateral, entering our premises, issuing any default notices to us, or attempting to exercise any other remedies
under the MDC Agreement or the Security Agreement. On August 9, 2017, the parties have stipulated to continue the provisions of
the TRO in full force and effect until further order of the appropriate court, which the Bankruptcy Court signed that same day
(the “Stipulated Order”).
On January 22, 2018, Savant wrote to the
Bankruptcy Court requesting dissolution of the TRO and the Stipulated Order. On January 29, 2018, the Bankruptcy Court granted
the Motion to Remand and denied Savant’s request to dissolve the TRO and Stipulated Order, ordering that any request to dissolve
the TRO and Stipulated Order be made to the Delaware Court.
On February 13, 2018 Savant made a letter
request to the Delaware Court to dissolve the TRO and Stipulated Order. Also, on February 13, 2018, the Company filed its Answer
and Affirmative defenses to Savant’s Counterclaims. On February 15, 2018 the Company filed a letter opposition to Savant’s
request to dissolve the TRO and Stipulated Order and requesting a status conference. A hearing on Savant’s request to dissolve
the TRO and Stipulated Order was held before the Delaware Court on March 19, 2018. The Delaware Court denied Savant’s request
to dissolve the TRO and Stipulated order, which remain in effect.
On April 11, 2018, the Company advised the
Delaware Court that it would meet and confer with Savant regarding a proposed case management order and date for trial. On April
26, 2018 the Delaware Court so-ordered a proposed case management order submitted by the Company and Savant. The schedule in the
case management order was modified by stipulation on August 24, 2018.
On April 8, 2019, the Company moved to compel
Savant to produce documents in response to the Company’s document requests. The parties thereafter agreed to a discovery
schedule through June 30, 2019, which the Superior Court so-ordered, and the parties produced documents to each other.
On June 4, 2019, Savant filed a complaint
against the Company and Madison in the Delaware Court of Chancery (the “Chancery Action”) seeking to “recover
as damages that amounts owed to it under the MDC Agreement, and to reclaim Savant’s intellectual property,” among other
things. Savant also requested leave to move to dismiss the Company’s complaint on the grounds that the Company’s
transfer of assets to Madison was champertous. On June 10, 2019, the Company requested by letter that the Superior Court
hold a contempt hearing because the Chancery Action violated the TRO entered by the Bankruptcy Court, the terms of which have been
extended by stipulation of the parties. On June 18, 2019, the Superior Court held a telephonic status conference. The
parties agreed that the Chancery Action should be consolidated with the Superior Court action, after which the Superior Court would
address the parties’ motions.
On July 22, 2019, the Company moved for
contempt against Savant. Savant filed its opposition on July 29, 2019. On August 12, 2019, the Superior Court denied
the Company’s motion for contempt.
On July 23, 2019, Savant moved for summary
judgment on the issue of champerty. The Company filed its response and cross-motion for summary judgment on August 27, 2019.
Savant filed its reply on September 10, 2019 and the Company filed its cross-reply on September 20, 2019. The motion is fully
briefed and was argued at a hearing on February 3, 2020. The court has not yet ruled on the motion.
On July 26, 2019, the Company moved to modify
the previously agreed-upon discovery schedule to extend discovery through December 31, 2019, which the Superior Court granted.
In subsequent orders, the discovery schedule was further extended until the end of June 2020.
On July 30, 2019, the Company filed a motion
to dismiss Savant’s Chancery Action. Savant filed an amended complaint on September 4, 2019, and the Company filed
its opening brief in support of its motion to dismiss on October 11, 2019. That motion is fully briefed and was argued at
a hearing on February 3, 2020. The court has not yet ruled on the motion.
On August 19, 2019, Savant moved to dismiss
the Company’s amended Superior Court complaint. On September 27, 2019, the Company filed an opposition to Savant’s
motion and, in the alternative, requested leave to file a second amended complaint against Savant. Savant consented to the
filing of the second amended complaint and withdrew their motion to dismiss. Savant filed a partial motion to dismiss against
a co-defendant on October 30, 2019. That motion is fully briefed and was argued at a hearing on February 3, 2020. At the
February 3, 2020 hearing, the Court reserved judgment on the parties’ reciprocal motions.
On May 22, 2020, upon the request of the
parties, the Superior Court stayed both Delaware actions until July 29, 2020.
On June 30, 2020, Savant exercised 20,000
warrants in a cashless exercise resulting in 10,909 shares being issued to Savant.
On July 24, 2020, the parties submitted
a joint status report in the Delaware actions. The parties also requested a status conference with the Court to discuss moving
the trial from October 2020 to some later time.
On August 20, 2020, the Court held the requested
status conference and ordered that a consolidated trial for the Superior Court Action and Chancery Action would be held in April
2021. The parties subsequently agreed to a five-day trial starting on April 12, 2021.
On October 7, 2020, Savant moved for leave
to amend its complaint in the Chancery Action to add a claim for breach of contract related to its exercise of 20,000 warrants.
Savant claims that the Company’s issuance of 10,909 shares was insufficient under the warrant.
Private Placement Litigation
On June 15, 2020, a
complaint was filed against Humanigen and Dr. Durrant in the Commercial Division of the Supreme Court of the State of New York.
The case caption is Alliance Texas Holdings, LLC et al. v. Humanigen, Inc. et al., Index No. 652490/2020 (“Alliance
Texas Holdings Case”). The plaintiffs in the Alliance Texas Holdings Case comprise a group of 17 prospective investors introduced
to Humanigen by Noble Capital Markets, Inc. (“Noble”), which had been engaged as a non-exclusive placement agent in
connection with the Private Placement. The plaintiffs had indicated interest in purchasing shares of common stock in the Private
Placement but, due to the strength of demand for shares from other prospective investors introduced to the company by J.P. Morgan
Securities LLC, the lead placement agent for the Private Placement, the plaintiffs were not allocated any investment amount. The
plaintiffs allege that the Company and Dr. Durrant breached a contractual obligation to deliver shares of common stock to the plaintiffs.
The plaintiffs seek to recover for losses due to alleged fraudulent misstatements and the Company’s failure to deliver shares
to them, and seek equitable relief in the form of specific performance. The Defendants filed a Motion to Dismiss the Complaint
in the Alliance Texas Holdings Case on July 24, 2020. The Parties completed briefing on the Motion to Dismiss on September 4, 2020.
The Motion to Dismiss is currently being considered by the court.
On June 19, 2020, Noble
filed a separate complaint against Humanigen in the Circuit Court of the Fifteenth Judicial Circuit in and for Palm Beach County,
Florida, also arising from the Private Placement. On July 13, 2020, the Defendants removed Noble’s complaint to United States
District Court for the Southern District of Florida. The case caption is Noble Capital Markets, Inc. v. Humanigen, Inc.,
Case No. 9:20-CV-81131-WPD (the “Noble Case”). Noble’s complaint alleges that Humanigen breached the terms of
its engagement letters with Noble by refusing to pay it the sales commissions it would have earned had its prospective investors
received the entire allocation of shares sought in the Private Placement, as opposed to the $4 million of shares actually allocated
to Noble and its clients. Noble is seeking payment in full of the commission, damages for Humanigen’s alleged tortious interference
with Noble’s business relationship with the investors it introduced to Humanigen, but which were not allocated shares in
the Private Placement, and attorneys’ fees. The Defendants filed a Motion to Dismiss Counts II-V of the Complaint in the
Noble Case on July 20, 2020. The Parties completed briefing on the Motion to Dismiss on August 26, 2020. The Motion to Dismiss
is currently being considered by the court.
The Company believes
that the claims made in each complaint are without merit, and it is prepared to defend itself vigorously.
10. Subsequent Events
On October 5, 2020, the Company’s
Compensation Committee determined that the Company had achieved or exceeded the original fiscal year 2020 performance criteria
and objectives, previously established in connection with the Company’s 2020 annual incentive plan. As a result, the Board
(with Dr. Cameron Durrant, the Company’s Chairman and Chief Executive Officer, abstaining) unanimously approved the acceleration
of the payout of a portion of Dr. Durrant’s fiscal year 2020 bonus. Dr. Durrant will remain eligible to receive additional
payouts under the 2020 annual incentive plan to the extent the Board determines that the Company has achieved certain additional
and stretch goals for 2020.
Based on the Company’s achievement
of certain pre-established fiscal year 2020 performance criteria and objectives, Dr. Durrant was awarded a fiscal year 2020 bonus
of $1,512,000, with 50% of such bonus being paid in cash and 50% being awarded in stock options. The options were fully vested
on the grant date.
On
October 13, 2020 the Company announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, launched its
ACTIV-5 "Big Effect Trial" (ACTIV-5/BET), designed to determine whether certain approved therapies or investigational
drugs in late-stage clinical development show promise against COVID-19 and, therefore, merit advancement into larger clinical trials.
ACTIV-5/BET, which is expected to enroll at as many as 40 US sites, will evaluate lenzilumab with remdesivir, compared to placebo
and remdesivir, in hospitalized COVID-19 patients with approximately 100 patients expected to be assigned to each study arm. Humanigen
is providing lenzilumab for the study, which is fully funded by NIH.
On October 29, 2020, the Company entered
into an amended and restated employment agreement (the “New Agreement”) with Dr. Durrant. The New Agreement replaces
Dr. Durrant’s previous employment agreement with the Company (the “Prior Agreement”).
Consistent with the terms of the Prior Agreement,
the New Agreement provides that Dr. Durrant’s annual base salary will remain at $600,000 and he will remain eligible for
an annual bonus targeted at 60% of his base salary, with Dr. Durrant’s base salary and target bonus subject to review by
the Board in connection with its regular review of the Company’s executive compensation program. The New Agreement provides
for a term ending December 31, 2021, with such term extending automatically for successive one year terms thereafter unless either
Dr. Durrant or the Company gives six months prior notice of non-renewal.
Under the New Agreement, Dr. Durrant is
entitled to receive certain benefits upon termination of employment under certain circumstances. If the Company terminates Dr.
Durrant’s employment for any reason other than “Cause”, or if Dr. Durrant resigns for “Good Reason”
(each as such term is defined in the New Agreement), Dr. Durrant will receive a lump sum payment equal to the sum of (i) his then-current
annual salary and (ii) the amount of the annual bonus earned by Dr. Durrant for the year prior to the year of termination.
The New Agreement additionally provides
that if Dr. Durrant resigns for Good Reason or the Company terminates his employment other than for Cause within the three month
period prior to or the two year period following a change in control (as such term is defined in the New Agreement), the Company
must pay or cause its successor to pay Dr. Durrant a lump sum cash payment equal to two times (a) his annual salary plus (b) the
aggregate bonus received by Dr. Durrant for the year immediately preceding the change in control. In addition, upon such a resignation
or termination, Dr. Durrant will also be entitled to be reimbursed for certain monthly health plan continuation premiums for up
to 18 months, and all outstanding stock options held by Dr. Durrant will immediately vest and become exercisable.
On
November 3, 2020, the Company entered into a License Agreement (the “License Agreement”) with KPM Tech Co., Ltd. (“KPM
Tech”) and its affiliate, Telcon RF Pharmaceutical, Inc. (together with KPM Tech, the “Licensee”). Pursuant to
the License Agreement, among other things, the Company granted the Licensee a license under certain patents and other intellectual
property to develop and commercialize the Company’s lead product candidate, lenzilumab, for treatment of COVID-19 pneumonia,
in South Korea and the Philippines, subject to certain reservations and limitations. The Licensee will be responsible for gaining
regulatory approval for, and subsequent commercialization of, lenzilumab in those territories.
As
consideration for the license, the Licensee has agreed to pay the Company (i) an up-front license fee of $6.0 million,
payable promptly following the execution of the License Agreement, (ii) up to an aggregate of $14.0 million in two payments
based on achievement by the Company of two specified milestones in the US, and (iii) subsequent to the receipt by the
Licensee of the requisite regulatory approvals, double-digit royalties on the net sales of lenzilumab in South Korea and the
Philippines. The Licensee has agreed to certain development and commercial performance obligations. It is expected that the
Company will supply lenzilumab to the Licensee for a minimum of 7.5 years at a cost plus basis from an existing or future
manufacturer. The Licensee has agreed to certain minimum purchases of lenzilumab on an annual basis.
On
November 5, 2020, the Company and the Department of Defense
(DoD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND or JPEO) entered
into a Cooperative Research and Development Agreement (“CRADA”) in collaboration with the Biomedical Advanced Research
and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S.
Department of Health and Human Services (HHS), in support of Operation Warp Speed (“OWS”), to assist in the development
of lenzilumab in advance of a potential Emergency Use Authorization (“EUA”) for COVID-19.
Pursuant
to the CRADA, the Company will be provided access to a full-scale, integrated team of OWS manufacturing, and regulatory subject
matter experts, leading decision makers and statistical support in anticipation of applying for EUA and subsequently a Biologics
License Application (“BLA”), for lenzilumab as a potential treatment for COVID-19. The CRADA also provides that OWS
regulatory experts will work with the Company on U.S. Food and Drug Administration (FDA) communications, meetings and regulatory
filings. The CRADA aims to support the ongoing lenzilumab Phase 3 clinical trials, focusing on efficiently generating an EUA and
BLA submission. In addition to providing access under EUA, a goal of the CRADA is to ensure lenzilumab receives the benefits provided
by Public Law 115-92.